Author

D. Maddalo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. J. Stein· 1 shared A. Lima· 1 shared B. H. Liu· 1 shared B. Kruspig· 1 shared C. Budjan· 1 shared C. Gao· 1 shared C. Miller· 1 shared C. Nixon· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. J. Stein

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinoma

S. Laing, B. Kruspig, R. Shaw, L. Officer-Jones, S. Edwards, D. McKinven, Y.-C. Hsieh, I. Powley, N. Brady, R. Pennie, R. Kwan, A. Lima, S. Myrta, M. Periyasamy, I. C. Dye, , D. J. Murphy

The paper investigates how ERBB signaling contributes to immune evasion in KRAS-driven lung adenocarcinoma using a novel mouse model and finds that transient ERBB blockade can restore immune surveillance when combined with PD1 blockade.

bioRxiv · Jul 24, 2023 · PreprintCancer Biology

SALLB not targeted by IMiDs is important for maintenance of liver cancer cells

K. A. L. Vu, S. Moein, K. Kumari, B. H. Liu, C. Gao, M. Liu, M.-Y. Dai, Z. Liu, F. Li, J. P. Tang, D. Maddalo, D. S. Auld, D. E. Casalena, X. Tian, M. A. Bassal, , L. Chai

The paper identifies a compound that degrades both SALL4 isoforms, overcoming IMiD limitations in liver cancer treatment.

bioRxiv · Jul 7, 2023 · PreprintCancer Biology